CD30 biAb-AATC / Medical College of Wisconsin, Tundra Targeted Therap - LARVOL DELTA

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Medical College of Wisconsin | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2028 ➔ Jul 2029 | Trial primary completion date: Jan 2027 ➔ Jan 2028

Enrollment open • First-in-human • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

CD30biAb-AATC for CD30+ Malignancies (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Medical College of Wisconsin | Phase classification: P1/2 ➔ P1 | Trial completion date: Jan 2027 ➔ Jul 2028

Phase classification • Trial completion date • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

CD30biAb-AATC for CD30+ Malignancies (clinicaltrials.gov) - P1/2 | N=42 | Not yet recruiting | Sponsor: Medical College of Wisconsin

New P1/2 trial • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Germ Cell Tumors • Hematological Malignancies • Leukemia • Lymphoma • Neuroblastoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • Sarcoma • Solid Tumor • CSF2 • TNFRSF8